TY - JOUR
T1 - Phase II trial of 5-FU, vincristine, and mitomycin (FoMi) in metastatic bronchioloalveolar cell lung cancer
T2 - A southwest oncology group study
AU - Miller, T. P.
AU - Livingston, R. B.
PY - 1985
Y1 - 1985
N2 - Twenty-three previously untreated patients with bronchioloalveolar cell lung cancer who had measurable disease and distant metastases (stage IIIM1, extensive) were treated with combination chemotherapy including 5-FU, vincristine, and mitomycin. Two of 23 patients (9%) achieved partial response lasting 5 and 6 months. Two patients (9%) died of sepsis while neutropenic. The current study does not justify the use of 5-FU, vincristine, and mitomycin combination chemotherapy in patients with metastatic bronchioloalveolar cell lung cancer.
AB - Twenty-three previously untreated patients with bronchioloalveolar cell lung cancer who had measurable disease and distant metastases (stage IIIM1, extensive) were treated with combination chemotherapy including 5-FU, vincristine, and mitomycin. Two of 23 patients (9%) achieved partial response lasting 5 and 6 months. Two patients (9%) died of sepsis while neutropenic. The current study does not justify the use of 5-FU, vincristine, and mitomycin combination chemotherapy in patients with metastatic bronchioloalveolar cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0022406155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022406155&partnerID=8YFLogxK
M3 - Article
C2 - 3004726
AN - SCOPUS:0022406155
SN - 0361-5960
VL - 69
SP - 1313
EP - 1314
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 11
ER -